JP2018522040A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2018522040A5 JP2018522040A5 JP2018505461A JP2018505461A JP2018522040A5 JP 2018522040 A5 JP2018522040 A5 JP 2018522040A5 JP 2018505461 A JP2018505461 A JP 2018505461A JP 2018505461 A JP2018505461 A JP 2018505461A JP 2018522040 A5 JP2018522040 A5 JP 2018522040A5
- Authority
- JP
- Japan
- Prior art keywords
- cd62l high
- composition
- cells
- combination according
- ccr7
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 101001018097 Homo sapiens L-selectin Proteins 0.000 claims description 51
- 102100033467 L-selectin Human genes 0.000 claims description 51
- 102100036301 C-C chemokine receptor type 7 Human genes 0.000 claims description 28
- 101000716065 Homo sapiens C-C chemokine receptor type 7 Proteins 0.000 claims description 28
- 238000000034 method Methods 0.000 claims description 26
- 210000001744 T-lymphocyte Anatomy 0.000 claims description 25
- 102000004269 Granulocyte Colony-Stimulating Factor Human genes 0.000 claims description 24
- 108010017080 Granulocyte Colony-Stimulating Factor Proteins 0.000 claims description 24
- 239000000203 mixture Substances 0.000 claims description 23
- 210000004027 cell Anatomy 0.000 claims description 20
- 239000003112 inhibitor Substances 0.000 claims description 17
- 102100032912 CD44 antigen Human genes 0.000 claims description 16
- 108010024212 E-Selectin Proteins 0.000 claims description 16
- 102100023471 E-selectin Human genes 0.000 claims description 16
- 101000868273 Homo sapiens CD44 antigen Proteins 0.000 claims description 16
- LYSYOXNOOPBOSC-NGSKMYNLSA-N (2S)-2-[(2R,3R,4R,5R,6R)-3-acetamido-2-[(1R,2R,3S,5R)-3-ethyl-5-[2-[3-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-(2-methoxyethoxy)ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]propanoylamino]ethylcarbamoyl]-2-[(2S,3S,4R,5S,6S)-3,4,5-trihydroxy-6-methyloxan-2-yl]oxycyclohexyl]oxy-5-hydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-3-cyclohexylpropanoic acid Chemical group C([C@H](O[C@H]1[C@@H](O)[C@@H](CO)O[C@H]([C@@H]1NC(C)=O)O[C@@H]1C[C@@H](C[C@@H]([C@H]1O[C@H]1[C@H]([C@H](O)[C@H](O)[C@H](C)O1)O)CC)C(=O)NCCNC(=O)CCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOC)C(O)=O)C1CCCCC1 LYSYOXNOOPBOSC-NGSKMYNLSA-N 0.000 claims description 12
- 208000023275 Autoimmune disease Diseases 0.000 claims description 8
- -1 CD45RO Proteins 0.000 claims description 8
- 206010028980 Neoplasm Diseases 0.000 claims description 8
- 201000011510 cancer Diseases 0.000 claims description 8
- 208000015181 infectious disease Diseases 0.000 claims description 8
- 210000005259 peripheral blood Anatomy 0.000 claims description 5
- 239000011886 peripheral blood Substances 0.000 claims description 5
- 230000028993 immune response Effects 0.000 claims description 4
- 230000001483 mobilizing effect Effects 0.000 claims description 3
- 239000000592 Artificial Cell Substances 0.000 claims description 2
- 102100028990 C-X-C chemokine receptor type 3 Human genes 0.000 claims description 2
- 102100027207 CD27 antigen Human genes 0.000 claims description 2
- 208000035473 Communicable disease Diseases 0.000 claims description 2
- 101000916050 Homo sapiens C-X-C chemokine receptor type 3 Proteins 0.000 claims description 2
- 101000914511 Homo sapiens CD27 antigen Proteins 0.000 claims description 2
- 101000914514 Homo sapiens T-cell-specific surface glycoprotein CD28 Proteins 0.000 claims description 2
- 101000611023 Homo sapiens Tumor necrosis factor receptor superfamily member 6 Proteins 0.000 claims description 2
- 102100022339 Integrin alpha-L Human genes 0.000 claims description 2
- 108010064548 Lymphocyte Function-Associated Antigen-1 Proteins 0.000 claims description 2
- 102100027213 T-cell-specific surface glycoprotein CD28 Human genes 0.000 claims description 2
- 102100040403 Tumor necrosis factor receptor superfamily member 6 Human genes 0.000 claims description 2
- 230000010261 cell growth Effects 0.000 claims description 2
- 208000024908 graft versus host disease Diseases 0.000 claims description 2
- 239000001963 growth medium Substances 0.000 claims description 2
- 238000002054 transplantation Methods 0.000 claims description 2
- 102000003800 Selectins Human genes 0.000 claims 1
- 108090000184 Selectins Proteins 0.000 claims 1
- 230000007115 recruitment Effects 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 description 2
- 238000012258 culturing Methods 0.000 description 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201562200628P | 2015-08-03 | 2015-08-03 | |
| US62/200,628 | 2015-08-03 | ||
| PCT/US2016/045139 WO2017023918A1 (en) | 2015-08-03 | 2016-08-02 | Methods for the mobilization and use of t-cells with enhanced reconstitution potential and life-span |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2018522040A JP2018522040A (ja) | 2018-08-09 |
| JP2018522040A5 true JP2018522040A5 (https=) | 2019-09-12 |
Family
ID=57943984
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2018505461A Pending JP2018522040A (ja) | 2015-08-03 | 2016-08-02 | 増強された再構成能および寿命を有するｔ細胞の動員および使用のための方法 |
Country Status (4)
| Country | Link |
|---|---|
| US (1) | US20180228871A1 (https=) |
| EP (1) | EP3331539A4 (https=) |
| JP (1) | JP2018522040A (https=) |
| WO (1) | WO2017023918A1 (https=) |
Families Citing this family (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US11433086B2 (en) | 2016-08-08 | 2022-09-06 | Glycomimetics, Inc. | Combination of T-cell checkpoint inhibitors with inhibitors of e-selectin or CXCR4, or with heterobifunctional inhibitors of both E-selectin and CXCR4 |
| AU2017341065B2 (en) | 2016-10-07 | 2023-04-06 | Crescent Biopharma, Inc. | Highly potent multimeric E-selectin antagonists |
| EP3596096A1 (en) | 2017-03-15 | 2020-01-22 | GlycoMimetics, Inc. | Galactopyranosyl-cyclohexyl derivatives as e-selectin antagonists |
| JP7275131B2 (ja) | 2017-11-30 | 2023-05-17 | グリコミメティクス， インコーポレイテッド | 骨髄浸潤リンパ球を動員する方法、およびその使用 |
| KR20200104889A (ko) | 2017-12-29 | 2020-09-04 | 글리코미메틱스, 인크. | E-셀렉틴 및 갈렉틴-3의 이종이기능성 억제제 |
| KR20200128025A (ko) * | 2018-03-05 | 2020-11-11 | 글리코미메틱스, 인크. | 급성 골수성 백혈병 및 관련 병태의 치료 방법 |
| CN113286811B (zh) * | 2018-07-30 | 2024-12-06 | 南加利福尼亚大学 | 改善过继性细胞疗法的效力和安全性 |
| US11845771B2 (en) | 2018-12-27 | 2023-12-19 | Glycomimetics, Inc. | Heterobifunctional inhibitors of E-selectin and galectin-3 |
| CN111789868B (zh) * | 2019-04-08 | 2022-07-19 | 深圳宾德生物技术有限公司 | 青蒿素类化合物在促进嵌合抗原受体t细胞治疗中的应用及药物组合物 |
| KR102081585B1 (ko) * | 2019-05-16 | 2020-02-26 | (주)녹십자셀 | 활성화 림프구 및 이의 제조 방법 |
| US20220265691A1 (en) * | 2019-07-12 | 2022-08-25 | Glycomimetics, Inc. | Methods for use of gene expression as an indicator of e-selectin inhibitor efficacy and clinical outcome for multiple tumor types |
| ES3063748T3 (en) * | 2019-07-31 | 2026-04-20 | Crescent Biopharma Inc | E-selectin antagonists for use in enhancing the survival of reconstituted, bone marrow-depleted hosts |
-
2016
- 2016-08-02 JP JP2018505461A patent/JP2018522040A/ja active Pending
- 2016-08-02 EP EP16833728.5A patent/EP3331539A4/en not_active Withdrawn
- 2016-08-02 WO PCT/US2016/045139 patent/WO2017023918A1/en not_active Ceased
- 2016-08-02 US US15/750,013 patent/US20180228871A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2018522040A5 (https=) | ||
| Shimasaki et al. | Expanded and armed natural killer cells for cancer treatment | |
| Scully et al. | NK cells in HIV disease | |
| Morandi et al. | NK cells of human secondary lymphoid tissues enhance T cell polarization via IFN‐γ secretion | |
| Sangiolo | Cytokine induced killer cells as promising immunotherapy for solid tumors | |
| Liu et al. | CRISPR/Cas9 genome editing: Fueling the revolution in cancer immunotherapy | |
| Rüter et al. | Immune modulation with weekly dosing of an agonist CD40 antibody in a phase I study of patients with advanced solid tumors | |
| Haworth et al. | Going back to class I: MHC and immunotherapies for childhood cancer | |
| Berger et al. | Adoptive transfer of virus-specific and tumor-specific T cell immunity | |
| Oevermann et al. | Immune reconstitution and strategies for rebuilding the immune system after haploidentical stem cell transplantation | |
| Grupp et al. | T cells engineered with a chimeric antigen receptor (CAR) targeting CD19 (CTL019) have long term persistence and induce durable remissions in children with relapsed, refractory ALL | |
| JP2014087372A5 (https=) | ||
| JP2017512484A5 (https=) | ||
| JP2017535261A5 (https=) | ||
| JP2018509163A5 (https=) | ||
| JP2016539929A5 (https=) | ||
| Ayed et al. | Immunotherapy for multiple myeloma: current status and future directions | |
| JP2017533707A5 (https=) | ||
| Du et al. | Regulatory T cells: concept, classification, phenotype, and biological characteristics | |
| Turtle et al. | Therapy of B cell malignancies with CD19-specific chimeric antigen receptor-modified T cells of defined subset composition | |
| JP2018531016A5 (https=) | ||
| Lugli et al. | Tissue‐resident and memory properties of human T‐cell and NK‐cell subsets | |
| JP2013536232A5 (https=) | ||
| Caserta et al. | IL‐7 is superior to IL‐2 for ex vivo expansion of tumour‐specific CD4+ T cells | |
| Gress et al. | Proceedings from the National Cancer Institute's Second International Workshop on the Biology, Prevention, and Treatment of Relapse after Hematopoietic Stem Cell Transplantation: Part I. Biology of Relapse after Transplantation |